Ghana
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 8.63 (7.19 - 10.34) | 2015 | Modelled | WHO |
| 8.36 | 2019 | Modelled | Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A systematic review and meta-analysis |
| 10.3 (6.90 - 11.40) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 12.3 (11.30 - 13.40) | 2015 | Modelled | Ofori-Asenso and Agyeman, 2016 |
| 12.92 (12.44 - 13.42) | 2013 | Modelled | Schweitzer et al, 2015 |
| 9.07 (8.28 - 9.92) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 9.65 (8.84 - 10.38) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.67 (8.83 - 10.49) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.34 (9.48 - 11.12) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.06 (10.06 - 11.94) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.3 (10.32 - 12.14) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.7 (10.68 - 12.57) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.16 (11.10 - 13.10) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.56 (11.41 - 13.61) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.79 (11.58 - 13.90) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.05 (11.87 - 14.13) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.51 (12.35 - 14.59) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.05 (12.86 - 15.14) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.52 (13.27 - 15.66) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.79 (13.53 - 16.03) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.03 (13.78 - 16.22) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.46 (14.15 - 16.70) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.94 (14.61 - 17.22) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.38 (14.97 - 17.73) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.63 (15.19 - 18.05) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.73 (15.39 - 18.16) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.83 (15.51 - 18.21) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.92 (15.63 - 18.29) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.02 (15.72 - 18.46) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.11 (15.78 - 18.58) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.22 (15.92 - 18.66) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.34 (16.03 - 18.73) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.47 (16.17 - 18.86) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.6 (16.25 - 19.01) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.74 (16.36 - 19.20) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.65 (8.81 - 10.56) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.61 (2.50 - 5) | 2015 | Modelled | WHO |
| 0.55 | 2019 | Modelled | Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A systematic review and meta-analysis |
| 0.64 (0.50 - 0.80) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.71 (0.56 - 0.88) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.74 (0.58 - 0.90) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.79 (0.62 - 0.97) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.04 (0.84 - 1.28) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.38 (1.10 - 1.70) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.30 - 1.95) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.47 - 2.18) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.97 (1.62 - 2.39) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.12 (1.76 - 2.58) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.24 (1.85 - 2.75) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.33 (1.93 - 2.82) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.4 (1.98 - 2.85) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.46 (2.03 - 2.91) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.54 (2.08 - 3.03) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.67 (2.19 - 3.21) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.77 (3.12 - 4.51) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.11 - 7.41) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.03 (7.49 - 10.79) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.45 (9.43 - 13.74) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.63 (10.38 - 15.23) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.86 (10.57 - 15.40) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.01 (10.73 - 15.50) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.13 (10.75 - 15.54) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.22 (10.79 - 15.64) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.32 (10.75 - 15.74) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.44 (10.92 - 15.89) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.55 (11.19 - 16.06) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.67 (11.30 - 16.17) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.78 (11.43 - 16.24) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.89 (11.57 - 16.31) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.13 (1.75 - 2.56) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 2,897,000 (1,938,000 - 3,227,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 2,860,620 (2,611,590 - 3,127,380) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2,957,840 (2,700,170 - 3,230,340) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,893,150 (2,653,340 - 3,107,630) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,834,920 (2,589,420 - 3,075,920) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,966,290 (2,719,020 - 3,190,730) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,104,590 (2,832,460 - 3,352,020) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,099,960 (2,832,230 - 3,332,050) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,135,380 (2,862,050 - 3,371,980) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,179,460 (2,896,060 - 3,422,640) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,203,000 (2,904,860 - 3,469,550) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,178,740 (2,876,300 - 3,456,670) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,155,780 (2,869,460 - 3,417,430) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,177,410 (2,901,880 - 3,430,940) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,210,850 (2,939,390 - 3,457,130) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,225,530 (2,948,930 - 3,483,700) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,193,100 (2,921,640 - 3,463,290) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,156,980 (2,894,990 - 3,407,190) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,159,380 (2,892,930 - 3,415,160) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,173,420 (2,906,400 - 3,424,810) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,174,180 (2,903,660 - 3,440,990) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,138,600 (2,865,410 - 3,407,280) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,078,160 (2,827,200 - 3,344,890) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,018,940 (2,779,860 - 3,264,500) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,961,540 (2,731,880 - 3,203,800) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,906,120 (2,687,740 - 3,151,010) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,852,880 (2,629,640 - 3,098,620) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,803,250 (2,592,960 - 3,034,430) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,757,260 (2,550,850 - 2,979,940) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,714,000 (2,509,390 - 2,926,620) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,672,830 (2,469,780 - 2,884,680) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,632,900 (2,428,560 - 2,845,850) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 9.89 (7.21 - 13.20) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 15.66 (11.10 - 22.15) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.58 (11.01 - 21.91) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.82 (11.27 - 22.15) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.94 (11.50 - 22.09) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.93 (11.64 - 21.91) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.85 (11.66 - 21.69) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.87 (11.78 - 21.56) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16.06 (12 - 21.28) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.94 (12.09 - 20.88) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.78 (12.19 - 20.26) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.57 (12.09 - 19.58) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.33 (12.10 - 18.91) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.96 (11.73 - 18.39) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.52 (11.35 - 17.81) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.96 (11.02 - 17.03) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.66 (10.86 - 16.73) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.17 (11.13 - 17.31) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.37 (10.60 - 16.37) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.06 (10.29 - 15.98) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.84 (10.10 - 15.61) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.72 (9.93 - 15.51) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.43 (9.71 - 15.13) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.81 (9.24 - 14.58) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.49 (8.15 - 13.21) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.08 (8.63 - 13.80) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.14 (7.74 - 12.94) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.11 (7.64 - 13.12) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.17 (7.60 - 13.40) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.95 (7.38 - 13.29) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.89 (7.21 - 13.17) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 5,108 | 2016 | Modelled | WHO |
| 2,408 (1,706 - 3,405) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,339 (1,653 - 3,291) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,569 (1,853 - 3,559) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,490 (1,774 - 3,486) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,629 (1,921 - 3,615) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,680 (1,972 - 3,666) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,903 (2,201 - 3,801) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,749 (2,041 - 3,734) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,851 (2,130 - 3,778) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,949 (2,278 - 3,785) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,986 (2,320 - 3,755) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,021 (2,384 - 3,726) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,029 (2,375 - 3,723) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,034 (2,382 - 3,705) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,022 (2,362 - 3,707) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,093 (2,459 - 3,788) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,074 (2,427 - 3,748) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,113 (2,469 - 3,814) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,127 (2,464 - 3,826) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,162 (2,487 - 3,842) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,217 (2,512 - 3,924) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,228 (2,522 - 3,929) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,148 (2,462 - 3,888) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,030 (2,360 - 3,775) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,943 (2,286 - 3,706) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,975 (2,249 - 3,861) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,913 (2,224 - 3,718) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,065 (2,289 - 4,036) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,069 (2,274 - 4,098) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,118 (2,273 - 4,155) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,118 (2,273 - 4,155) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 97 | 2019 | Survey/reported | WHO/UNICEF |
| 94 | 2020 | Survey/reported | WHO/UNICEF |
| 98 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Risk-based
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.5 (0.90 - 4.10) | 2015 | Modelled | Maaroufi et al, 2017 |
| 1.4 (1.10 - 3.40) | 2017 | Modelled | Sonderup et al, 2017 |
| 1.4 (1.10 - 3.40) | 2015 | Modelled | Blach et al, 2017 |
| 3.44 (2.75 - 4.35) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.45 (2.76 - 4.35) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.45 (2.77 - 4.37) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.45 (2.78 - 4.32) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.46 (2.77 - 4.33) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.48 (2.79 - 4.35) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.52 (2.82 - 4.42) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.56 (2.85 - 4.44) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.61 (2.90 - 4.51) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.65 (2.94 - 4.59) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.69 (2.99 - 4.60) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.73 (3.02 - 4.64) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.78 (3.06 - 4.69) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.83 (3.09 - 4.70) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.89 (3.12 - 4.74) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.96 (3.22 - 4.80) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.07 (3.35 - 4.86) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.18 (3.48 - 4.94) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.29 (3.58 - 5.07) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.37 (3.64 - 5.16) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.42 (3.68 - 5.22) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.48 (3.72 - 5.27) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.52 (3.75 - 5.36) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.55 (3.76 - 5.40) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.57 (3.75 - 5.43) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.57 (3.75 - 5.42) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.56 (3.73 - 5.42) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.55 (3.72 - 5.44) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.53 (3.68 - 5.44) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.5 (3.65 - 5.45) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.33 (2.65 - 4.20) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.83 (1.40 - 4.33) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.2 (0.50 - 8.10) | 2014 | Modelled | Riou et al, 2015 |
| 2 (1.20 - 5.50) | 2014 | Modelled | Maaroufi et al, 2017 |
| 3 (2.60 - 3.50) | 2015 | Modelled | Agyeman et al, 2016 |
| 3.2 (0.50 - 8.10) | 2017 | Modelled | Sonderup et al, 2017 |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 40.1 (34.80 - 45.40) | 2005 | Survey/reported | Adjei A et al, 2007 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 399,000 (305,000 - 944,000) | 2015 | Modelled | Blach et al, 2017 |
| 668,520 (540,666 - 808,090) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 688,198 (558,406 - 825,600) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 707,153 (577,752 - 846,073) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 725,556 (593,333 - 863,435) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 743,530 (610,290 - 881,899) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 761,276 (625,401 - 906,294) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 777,573 (642,356 - 922,786) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 791,315 (656,604 - 936,600) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 803,147 (668,018 - 946,391) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 813,816 (678,218 - 960,377) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 824,069 (687,341 - 973,649) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 830,783 (693,164 - 981,480) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 832,217 (692,302 - 983,648) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 831,586 (685,418 - 994,137) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 832,505 (676,945 - 1,007,580) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 839,022 (674,798 - 1,023,080) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 850,644 (687,876 - 1,042,590) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 863,723 (700,770 - 1,072,180) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 877,818 (710,290 - 1,092,100) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 892,413 (721,673 - 1,114,250) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 906,886 (730,949 - 1,139,520) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 919,711 (739,533 - 1,148,860) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 930,889 (745,663 - 1,162,850) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 942,008 (753,743 - 1,183,880) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 954,828 (764,663 - 1,193,070) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 971,284 (777,368 - 1,213,900) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 990,836 (796,382 - 1,240,190) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,012,360 (810,304 - 1,279,540) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,034,200 (830,030 - 1,303,150) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,048,760 (837,177 - 1,324,580) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1,055,200 (843,069 - 1,332,320) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 138,000 (106,000 - 328,000) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 1.75 (1.23 - 2.42) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.24 (1.50 - 3.19) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.25 (1.49 - 3.24) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.23 (1.50 - 3.16) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.21 (1.49 - 3.12) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.2 (1.50 - 3.12) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.19 (1.49 - 3.08) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.18 (1.55 - 2.96) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.19 (1.50 - 3.06) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.21 (1.54 - 3.02) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.17 (1.56 - 2.95) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.15 (1.56 - 2.92) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (1.53 - 2.85) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.05 (1.50 - 2.78) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.99 (1.45 - 2.70) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.94 (1.42 - 2.63) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.85 (1.35 - 2.51) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.9 (1.39 - 2.57) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.31 - 2.44) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.29 - 2.41) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.76 (1.27 - 2.36) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.26 - 2.35) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.25 - 2.36) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.25 - 2.35) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.27 - 2.43) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.27 - 2.43) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.76 (1.27 - 2.37) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.29 - 2.53) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.27 - 2.48) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.75 (1.23 - 2.42) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.24 - 2.46) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,090 | 2016 | Modelled | WHO |
| 552 (387 - 764) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 552 (387 - 764) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 548 (383 - 758) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 548 (388 - 762) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 529 (375 - 731) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 513 (364 - 699) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 500 (358 - 681) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 481 (347 - 647) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 465 (333 - 631) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 451 (324 - 610) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 441 (318 - 595) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 433 (312 - 580) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 426 (308 - 577) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 421 (304 - 569) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 419 (306 - 568) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 419 (306 - 566) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 416 (305 - 562) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 414 (302 - 563) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 414 (303 - 563) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 413 (302 - 562) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 412 (298 - 560) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 405 (292 - 551) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 398 (282 - 540) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 392 (273 - 536) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 379 (259 - 530) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 370 (253 - 521) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 363 (247 - 514) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 357 (240 - 503) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 351 (235 - 497) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 344 (230 - 490) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 338 (223 - 487) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Risk-based
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
3,118
2019
(2,273 - 4,155)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
552
2019
(387 - 764)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
2.13
(%)
2020, latest modelled
(1.75 - 2.56(%))
WHO
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
